Repligen Corporation ($RGEN) Stock Forecast: Up 5.9% Today

What is Repligen Corporation?

Repligen Corporation (RGEN) is a company specializing in bioprocessing technologies, aiming to improve process efficiency and flexibility. The company recently reached a 52-week low in its stock price but displayed resilience with robust Q4 2025 earnings and global expansion efforts.

Why is Repligen Corporation going up?

RGEN stock is up 5.9% on Apr 24, 2026 17:41

• Repligen Corporation's (RGEN) stock witnessed a positive movement despite a recent 52-week low.
• The CEO's sale of company shares under a 10b5-1 plan initially sparked concerns, but the market response appears favorable, potentially interpreted as a strategic decision.
• Favorable ratings and increased price targets from analysts, in addition to the anticipation of the upcoming financial results announcement, likely contributed to the optimistic sentiment surrounding RGEN.
• The market seems hopeful about the company's growth prospects, particularly following strong Q4 2025 earnings and the establishment of a new training center in the Netherlands, signaling global expansion.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Repligen Corporation stock hits 52-week low at 109.66 USD

Repligen Corporation (RGEN) stock has reached a 52-week low of $109.66, marking a 24.09% decrease over the past year. Despite this downturn, InvestingPro analysis suggests the shares are undervalued, and analysts maintain price targets ranging from $140 to $220. The company recently reported strong Q4 2025 earnings, surpassing expectations, and expanded its global presence with a new training center in the Netherlands.

https://www.investing.com/news/company-news/repligen-corporation-stock-hits-52week-low-at-10966-usd-93CH-4633653

Insider Sell: Olivier Loeillot Sells Shares of Repligen Corp (RGEN)

Olivier Loeillot, CEO of a Repligen Corp branch, sold 3,832 shares of the company on April 21, 2026, reducing his holding to 54,246 shares. This transaction is part of a trend of 8 insider sells against 1 insider buy over the past year for Repligen. The company's stock, trading at $140, is considered modestly undervalued with a price-to-GF-Value ratio of 0.81, despite a high P/E ratio compared to the industry median.

https://www.gurufocus.com/news/8810211/insider-sell-olivier-loeillot-sells-shares-of-repligen-corp-rgen

Repligen CEO Loeillot sells $536,480 in company stock

Repligen Corp CEO Olivier Loeillot recently sold 3,832 shares of company stock for $536,480, executed under a pre-arranged 10b5-1 trading plan. Following the sale, Loeillot directly holds 54,246 shares. Despite a year-to-date stock decline, the company reported strong Q4 2025 earnings, exceeding analyst expectations, and analysts have maintained positive ratings and raised price targets.

https://m.investing.com/news/insider-trading-news/repligen-ceo-loeillot-sells-536480-in-company-stock-93CH-4630248?ampMode=1

Repligen Corp (RGEN) CEO sells 3,832 shares under 10b5-1 plan

Repligen Corp's CEO, Olivier Loeillot, sold 3,832 shares of common stock at $140 per share in an open-market transaction on April 21, 2026. This sale was conducted under a Rule 10b5-1 trading plan, which pre-schedules trades to avoid accusations of insider trading. Following the transaction, Mr. Loeillot still directly holds 54,246 shares of Repligen common stock.

https://www.stocktitan.net/sec-filings/RGEN/form-4-repligen-corp-insider-trading-activity-0ad00edd83b5.html

Repligen to Report First Quarter 2026 Financial Results

Repligen Corporation (NASDAQ: RGEN) announced it will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET to discuss updates and results for the period ending March 31, 2026. A webcast of the call will be available on the Investor Relations section of Repligen’s website.

https://www.sahmcapital.com/news/content/repligen-to-report-first-quarter-2026-financial-results-2026-04-22

Trending Today

Wheat ($WHEAT) Commodity Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 7.3% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Down 4.9% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Repligen Corporation Price History

11.02.2026 - RGEN Stock was down 5.2%

• The bearish movement in RGEN's stock today could be attributed to concerns regarding declining operating margins and reduced return on invested capital, despite the company's improved earnings report.
• The participation of Repligen Corporation in upcoming investor conferences may have failed to reassure investors about the company's growth potential, leading to a negative sentiment in the market.
• Investors might be cautious about the company's ability to address challenges like scale disadvantages and margin pressure, which could be contributing to the bearish trend in RGEN's stock price today.

01.03.2026 - RGEN Stock was up 5.7%

• Repligen Corp (RGEN) experienced a strong bullish movement today.
• The bullish trend can be attributed to the company's impressive quarterly earnings report, surpassing expectations with $0.49 EPS and an 18.1% year-over-year revenue growth.
• Institutional ownership remains high at 97.64%, indicating continued confidence in the company's performance.
• Despite the sale of 30,070 shares by Riverbridge Partners LLC, the overall market sentiment towards Repligen remains positive, supported by its strategic positioning in the biopharma supply chain and strong financial health.

22.03.2026 - RGEN Stock was down 5.6%

• Today, Repligen Corporation (RGEN) witnessed a pronounced bearish movement in the market, likely influenced by the following factors:
• The pricing of capped notes by a financial institution linked to RGEN stock could have introduced uncertainty and potential downside risk, impacting investor sentiment.
• A recent Form 144 filing revealing a proposed resale of common shares by insiders might have triggered selling pressure and negative market perception.
• Despite its leadership in bioprocessing tools, positive analyst coverage, and a Buy rating from a prominent firm, the market movement might have been driven by profit-taking or concerns regarding valuation sensitivities in high-growth scenarios.
• Overall, a combination of these factors likely contributed to the bearish trend in RGEN stock today, notwithstanding its strong market position and growth prospects in the bioprocessing industry.

21.03.2026 - RGEN Stock was up 5.1%

• The bullish movement in Repligen Corp's stock (RGEN) today can be attributed to several factors:
• Analysts' positive views on the company's strong market position and recurring revenue model have likely boosted investor confidence.
• The initiation of coverage with a Buy rating and a price target upgrade by a notable firm highlights the company's bioprocessing strength and growth potential, further driving up the stock price.
• The opening of a new training and innovation center in the Netherlands showcases Repligen's commitment to enhancing customer support and expanding its technical capabilities, signaling future growth opportunities.
• Overall, Repligen's strategic initiatives, strong competitive position, and recent financial performance have likely contributed to the bullish market movement today.

04.02.2026 - RGEN Stock was up 6.1%

• Repligen's COO and CEO both had tax-withholding share dispositions, which could indicate a routine financial activity rather than a significant event impacting the company's fundamentals.
• Despite a recent drop in share price on February 27, analysts remain optimistic about Repligen, with a forecasted upside potential of around 45-47%.
• The mixed investor reactions to Repligen's strong Q4 2025 results and cautious 2026 guidance suggest uncertainty about the company's future performance, particularly regarding revenue and EPS projections.
• The recommendation to avoid investing in Repligen due to concerns about distribution channels, operating margins, and return on invested capital may have contributed to the bearish movement on February 27, but the overall bullish trend today could be attributed to the positive long-term outlook and potential growth opportunities in the bioprocessing industry.

24.03.2026 - RGEN Stock was up 5.9%

• Repligen Corporation's (RGEN) stock witnessed a positive movement despite a recent 52-week low.
• The CEO's sale of company shares under a 10b5-1 plan initially sparked concerns, but the market response appears favorable, potentially interpreted as a strategic decision.
• Favorable ratings and increased price targets from analysts, in addition to the anticipation of the upcoming financial results announcement, likely contributed to the optimistic sentiment surrounding RGEN.
• The market seems hopeful about the company's growth prospects, particularly following strong Q4 2025 earnings and the establishment of a new training center in the Netherlands, signaling global expansion.

17.02.2026 - RGEN Stock was up 5.0%

• Institutional confidence in Repligen Corporation surged as Iron Triangle Partners LP, Holocene Advisors LP, and Geneva Capital Management significantly increased their stakes in the company, reflecting strong growth prospects.
• Repligen reported stronger-than-expected Q3 earnings and revenue, surpassing quarterly estimates and providing optimistic FY2026 guidance, contributing to the bullish market movement.
• The projected boom in the Biological Product IgG Purification Medium Market, where Repligen is a key player, further fueled investor optimism and interest in the company's growth potential.
• Analysts maintaining a "Moderate Buy" consensus rating with a target price of $174.58 for Repligen amidst positive earnings reports and strategic investments also supported the bullish trend in the stock.

23.03.2026 - RGEN Stock was down 12.4%

• The CEO of Repligen Corp, Olivier Loeillot, sold 3,832 shares of the company, reducing his holding to 54,246 shares. This significant insider sell might have contributed to the bearish movement as it could signal lack of confidence in the company's future performance.
• Despite the CEO's sell-off, analysts have maintained positive ratings and raised price targets for Repligen, indicating underlying strength in the company's fundamentals.
• The upcoming earnings release on May 5, 2026, could also be a factor in the bearish movement as investors might be cautious ahead of the financial results, especially considering the recent insider selling activity.
• Overall, the combination of insider selling, upcoming earnings report, and market sentiment may have led to the bearish movement in Repligen Corp's stock today.

14.03.2026 - RGEN Stock was up 5.2%

• Repligen's stock (RGEN) saw a bullish trend after surpassing analyst expectations in Q3 earnings and revenue. This impressive financial performance likely boosted investor confidence and drove up the stock price.
• An in-depth financial analysis revealed that Filtration products significantly contribute to Repligen's overall sales, providing investors with insights into the company's revenue streams and growth opportunities.
• The market growth in the Hollow Fiber TFF Modules sector, where Repligen holds a key position, could have positively impacted RGEN's stock performance. Investors may perceive Repligen favorably within this expanding market segment, contributing to the bullish movement.

12.02.2026 - RGEN Stock was down 5.2%

• The bearish movement in RGEN's stock today could be attributed to concerns about potential valuation risks due to its high P/E ratio of 138x, significantly above the industry average.
• Despite the positive financial performance and exceeding earnings expectations, the pressure faced by healthcare stocks after a weak February jobs report might have contributed to the downward movement in RGEN's stock price.
• The increased stake by institutional investors like Geneva Capital Management LLC and Schroder Investment Management Group could indicate a vote of confidence in the company's long-term prospects, potentially mitigating some of the short-term bearish sentiment.
• Investors may be reevaluating RGEN's valuation and growth prospects in light of mixed sentiment and the need to carefully analyze the company's financial numbers amidst market uncertainties.

15.03.2026 - RGEN Stock was up 5.4%

• The bullish movement in RGEN's stock today can be attributed to the strong market trends in the bioprocessing sector and the growing demand for its specialized tools for biologics manufacturing.
• Analysts' positive views on Repligen's leadership in bioprocessing and the company's strategic acquisitions driving recurring revenue may have boosted investor confidence in its growth potential.
• The comprehensive enterprise analysis report on the Hollow Fiber TFF Modules Market, highlighting key players like Repligen Corporation, could have further emphasized the company's strong market position and growth prospects.
• The in-depth financial analysis showcasing RGEN's revenue breakdown, profitability margins, and comparison with competitors may have reassured investors of the company's solid financial performance, contributing to the bullish sentiment surrounding the stock.

31.02.2026 - RGEN Stock was up 5.8%

• Repligen Corp (RGEN) saw a significant bullish movement today.
• This upward trend may be linked to the company's impressive quarterly earnings, surpassing expectations with $0.49 EPS and an noteworthy 18.1% year-over-year revenue growth.
• Furthermore, the optimistic FY2026 EPS guidance shared by Repligen bolstered investor confidence in the company's future outlook.
• Despite institutional selling by Riverbridge Partners LLC, the substantial institutional ownership at 97.64% and analysts' "Moderate Buy" rating with a target price of $176.92 likely played a role in fostering the overall positive sentiment surrounding RGEN.